PT - JOURNAL ARTICLE AU - Gladstone, Jonathan P. AU - Dodick, David W. TI - Acute Migraine: Which Triptan? AID - 10.1111/j.1474-7766.2004.03-205.x DP - 2004 Feb 01 TA - Practical Neurology PG - 6--19 VI - 4 IP - 1 4099 - http://pn.bmj.com/content/4/1/6.short 4100 - http://pn.bmj.com/content/4/1/6.full SO - Pract Neurol2004 Feb 01; 4 AB - INTRODUCTION Primary headache disorders are the most frequent reason for referral to neurologists worldwide, and most of these patients have migraine (Menken 1996; Sempere et al. 2002; Rajput et al. 1988). Migraine is a common and frequently incapacitating headache disorder characterized by episodic attacks of moderate-to-severe headache, along with various combinations of neurological, gastrointestinal and autonomic symptoms (Goadsby et al. 2002). The one-year prevalence of migraine is 11% in the United States and Western Europe (6% for males and 15–18% for females) and one quarter of migraine patients experience one or more attacks per week (Goadsby et al. 2002; Hamelsky et al. 2001). A recent report by the World Health Organization ranks migraine as one of the most disabling chronic conditions and equates a day with severe migraine to the disability associated with a day with quadriplegia, psychosis or dementia (Menken et al. 2000).The aggregate impact of migraine